CCI vs MLYS · P/E 40, rev $2.02B vs $2.17B cap
Crown Castle (CCI) versus Mineralys Therapeutics, Inc. Common Stock (MLYS) — a side-by-side from cached financials, not a winner call.
Crown Castle (CCI) is a reit - specialty company listed on US.
Mineralys Therapeutics, Inc. Common Stock (MLYS) is a biotechnology company listed on US.
Latest reported CCI revenue for 2026-06-30 was $2.02B. Net income was $245.0M. Revenue was up 99.8% from 2026-03-31 to 2026-06-30. CCI currently screens at market cap $40.93B and trailing P/E 39.6.
MLYS does not have a complete income-statement cache yet.
CCI currently screens at market cap $40.93B and trailing P/E 39.6. MLYS currently screens at market cap $2.17B.
Not investment advice. Open the CCI and MLYS stock pages for the full models.
Not investment advice.